The healthcare system is the true loser if the FDA grants GT3 Sofo/Riba labeling based on this post-hoc analysis. Billions of dollars will be spent on retreatment costs. GT3 patients are supportive of early access to oral therapy until they are the unlucky ones to fail therapy and are left without an interferon-based option.
GILD now wants to charge payers double for treating GT3 patients for 24-weeks as opposed to 12-weeks needed with a suitable oral combo (Sofo/GS-5816, Sofo/IDX-719, etc.) or interferon-based therapy. The fallacy now is GILD will triple-dip treating failures if payers accept these terms.
Market Data 
Markets 
AI
